Albert D. Friesen Explained

Albert "Bert" D. Friesen, (born May 19, 1947) is a Canadian biotechnologist involved in biotechnology innovation.^[1] His biotechnology career began as the first full-time employee of the Winnipeg Rh Institute, where he later became president and CEO, and led the development of WinRho, one of Canada's first successful biotech products.^[2]

Education

Albert Friesen went to the University of Manitoba and earned a Ph.D. in protein chemistry.^[3]

Career

In 1987, Dr. Friesen was a founder and the company’s first board of directors Chairman at the Industrial Biotechnology Association of Canada (IBAC) which is now known as BIOTECanada.^[4]

In 1997, Friesen founded Medicure, which sells a large number of cardiovascular products. In 2020, Medicure purchased Marley Drug and the company can now sell medications directly to patients.

From 2014-2017, Friesen was chair on the International board of MEDA (Mennonite Economic Development Associates).

Notes and References

1. News: Local bio-entrepreneur to be honoured . . 2013-04-22 . 2016-07-20.
2. Web site: Manitoba's Bio Builder - Biotechnology FocusBiotechnology Focus | Biotechnology Focus – Leading change in Canada's life science industry, from innovation to business . Biotechnologyfocus.ca . 2013-09-06 . 2016-07-20.
3. Web site: Albert Friesen . 2024-11-27 . MEDA . en-US.
4. Web site: Albert Friesen BAM Outstanding Leadership in Bioscience . 2024-11-15 . Medicure Inc. . en.